Clinical Trial Update: Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing fixed-dose mycophenolate mofetil to concentration-controlled dosing in de novo kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Erasmus Medical Center | Conditions: De Novo Renal Transplant Recipient. | Phase 4 | Status: COMPLETED